Crossing the Chasm: How to Approach Translational Pharmacokinetic–Pharmacodynamic Modeling of Phage Dosing
Clinical Pharmacology & Therapeutics · 2025
DOI: 10.1002/cpt.3426 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical Pharmacology & Therapeutics, 2025. Verfasst von Gauri G Rao und 5 weiteren Autor:innen. Beteiligte Einrichtung: USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, California, USA. Hauptthemen laut MEDLINE: Bacteriophages, Phage Therapy, Anti-Bacterial Agents, Models, Biological. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 43 Literaturangaben.
Abstract (Originalsprache)
Effectively treating multidrug‐resistant bacterial infections remains challenging due to the limited drug development pipeline and a scarcity of novel agents effective against these highly resistant pathogens. Bacteriophages (phages) are a potential addition to the antimicrobial treatment arsenal. Though, phages are currently being tested in clinical trials for antibiotic‐resistant infections, phages lack a fundamental understanding of optimal dosing in humans. Rationally designed preclinical studies using in vitro and in vivo infection models, allow us to assess clinically relevant phage +/− antibiotic exposure (pharmacokinetics), the resulting treatment impact on the infecting pathogen (pharmacodynamics) and host immune response (immunodynamics). A mechanistic modeling framework allows us to integrate this knowledge gained from preclinical studies to develop predictive models. We reviewed recently published mathematical models based on in vitro and/or in vivo data that evaluate the effects of varying bacterial or phage densities, phage characteristics (burst size, adsorption rate), phage pharmacokinetics, phage–antibiotic combinations and host immune responses. In our review, we analyzed study designs and the data used to inform the development of these mechanistic models. Insights gained from model‐based simulations were reviewed as they help identify crucial phage parameters for determining effective phage dosing. These efforts contribute to bridging the gap between phage therapy research and its clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, California, USA.
- School of Biological Sciences, Monash University, Clayton, Victoria, Australia.
- Division of Infectious Diseases, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Gauri G Rao, Quentin Vallé
Zitieren
APA
Rao, G. G., Vallé, Q., Mahadevan, R., Sharma, R., Barr, J. J., & Van Tyne, D. (2025). Crossing the Chasm: How to Approach Translational Pharmacokinetic–Pharmacodynamic Modeling of Phage Dosing. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3426
Vancouver
Rao GG, Vallé Q, Mahadevan R, Sharma R, Barr JJ, Van Tyne D. Crossing the Chasm: How to Approach Translational Pharmacokinetic–Pharmacodynamic Modeling of Phage Dosing. Clinical Pharmacology & Therapeutics. 2025. doi:10.1002/cpt.3426
BibTeX
@article{Rao2025,
author = {Rao, Gauri G and Vallé, Quentin and Mahadevan, Ramya and Sharma, Rajnikant and Barr, Jeremy J and Van Tyne, Daria},
title = {Crossing the Chasm: How to Approach Translational Pharmacokinetic–Pharmacodynamic Modeling of Phage Dosing},
journal = {Clinical Pharmacology & Therapeutics},
year = {2025},
doi = {10.1002/cpt.3426}
}
EUVIMED